Floatz logo

8-AZABICYCLO(3.2.1)OCTANE-2-CARBOXYLIC ACID, 3-(4-FLUOROPHENYL)-8-((2E)-3-IODO-2-PROPEN-1-YL)-, METHYL ESTER, (1R,2S,3S,5S)-

Movement Disorders

GE HealthcareSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Movement Disorders cohort.

Asset / SponsorPhaseRating
LEVODOPA
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Phase 4BBB
TRIMETHOBENZAMIDE
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Phase 4BB
1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)-
Novartis Pharmaceuticals
Phase 2BB
APOMORPHINUM
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Phase 4BB
LEMBOREXANT
YangPan
Phase 4BB

View all 24 →

Same molecule, other indications

8-AZABICYCLO(3.2.1)OCTANE-2-CARBOXYLIC ACID, 3-(4-FLUOROPHENYL)-8-((2E)-3-IODO-2-PROPEN-1-YL)-, METHYL ESTER, (1R,2S,3S,5S)- is also rated in:

parkinsonian disorderDormant
B
Indicative ·
60 / 100
View asset →
Parkinson diseaseDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →